The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts

Leukemia

Volumn 27, Issue 4, 2013, Pages 889-896

  Nikpour, M ^a   Scharenberg, C ^a,b   Liu, A ^a   Conte, S ^a   Karimi, M ^a   Mortera Blanco, T ^a   Giai, V ^a   Fernandez Mercado, M ^c   Papaemmanuil, E ^d   Hogstrand K ^a   Jansson, M ^a   Vedin, I ^a   Stephen Wainscoat, J ^c   Campbell, P ^d,e   Cazzola, M ^f,g   Boultwood, J ^c   Grandien, A ^a   Hellstrom Lindberg E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SKARABORG HOSPITAL   (Sweden)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

Author keywords

ABCB7; acquired sideroblastic anemia; iron sulfur cluster biogenesis; mitochondrial ferritin (FTMT); RARS; SF3B1

Indexed keywords

ABCB7 PROTEIN; CD34 ANTIBODY; FERROPORTIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; DOWN REGULATION; ERYTHROBLAST; ERYTHROID CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; COHORT STUDIES; DOWN-REGULATION; EXONS; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; K562 CELLS; MALE; MIDDLE AGED; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RNA SPLICING;

EID: 84876107840     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.298     Document Type: Article

References (36)

1. Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101: 1996-2000.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
3. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
4. Hellstrom-Lindberg E, Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 2008; 52-59.
5. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
6. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG Pascutto C et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118: 6239-6246.
7. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569-572.
8. Thol F, Kade S, Schlarmann C, Lö ffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1 and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
9. Damm F, Thol F, Kosmider O, Kade S, Loffeld P, Dreyfus F et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012; 26: 1137-1140.
10. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
11. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001; 112: 714-726.
12. Schmidt-Mende J, Tehranchi R, Forsblom AM, Joseph B, Christensson B, Fadeel B et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001; 15: 742-751.
13. Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Galli A et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009; 114: 3538-3545.
14. Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101: 1080-1086.
15. Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106: 247-253.
16. Allikmets R, Raskind WH, Hutchinson A, Schueck ND, Dean M, Koeller DM. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999; 8: 743-749.
17. Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol 2009; 46: 371-377.
18. Cavadini P, Biasiotto G, Poli M, Levi S, Verardi R, Zanella I et al. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 2007; 109: 3552-3559.
19. Pondarre C, Antiochos BB, Campagna DR, Clarke SL, Greer EL, Deck KM et al. The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. Hum Mol Genet 2006; 15: 953-964.
20. Pondarre C, Campagna DR, Antiochos B, Sikorski L, Mulhern H, Abcb7 Fleming MD. the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 2007; 109: 3567-3569.
21. Nikpour M, Pellagatti A, Liu A, Karimi M, Malcovati L, Gogvadze V et al. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. Br J Haematol 2010; 149: 844-854.
22. Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008; 3: e1970.
23. Steensma DP, Hecksel KA, Porcher JC, Lasho TL. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts). Leuk Res 2007; 31: 623-628.
24. Persons DA, Allay JA, Allay ER, Smeyne RJ, Ashmun RA, Sorrentino BP et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 1997; 90: 1777-1786.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
26. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-542.
27. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589-595.
28. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
29. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010; 116: 945-952.
30. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44: 53-57.
31. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S et al. Gene expression profiles of CD34\+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006; 108: 337-345.
32. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803-811.
33. Nie G, Sheftel AD, Kim SF, Ponka P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 2005; 105: 2161-2167.
34. Ljung T, Back R, Hellstrom-Lindberg E. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. Haematologica 2004; 89: 1446-1453.
35. Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 2012 (doi: 10.3324/haematol.2012.072538).
36. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-3210.